宫腔镜手术是黏膜下肌瘤微创保守性的一线治疗方案，随着宫腔镜技术的推广普及、作为一种普遍开展的常见病手术类型，中国妇幼保健协会于2023年10月22日颁布了《宫腔镜下子宫肌瘤去除术管理规范》(T/CMCHA 002-2023)团体标准。旨在为宫腔镜下子宫肌瘤去除术的技术、管理、实施方面提供指导和支持。该标准对宫腔镜下子宫肌瘤去除术的医疗机构、团队人员、设备和环境提出了标准化要求。同时，该标准还规范了宫腔镜下子宫肌瘤去除术的临床技术标准，包括手术技术、培训制度、结果评价和质量控制管理等。本文对该团体标准中提出的要求与建议进行解读，以期为临床工作者更好地理解及应用标准、规范临床实践提供参考。

Hysteroscopic myomectomy (HM) is the first-line minimally invasive and conservative surgical treatment for submucosal leiomyomas, With the popularization of hysteroscopy technology, as a common surgical method for uterine fibroids, On October 22, 2023, the Chinese Maternal and Child Health Association issued the association standard "Management of hysteroscopic myomectomy" (T/CMCHA 002-2023), which providing guidance and support for the technique, management and implementation of hysteroscopic myomectomy. The standard puts forward standardized requirements for medical institutions, team personnel, equipment and environment of hysteroscopic myomectomy. Meanwhile, the standard also standardized the clinical technical standards for hysteroscopic myomectomy, including surgical techniques, training systems, results evaluation and quality control management. This article interprets the requirements and recommendations outlined in the standard, aiming to assist clinical workers in comprehending and implementing the standard in clinical practice in a standardized manner.